Current perspectives on cell-assisted lipotransfer for breast cancer patients after radiotherapy

Table 4 Patient demographics extracted from the three studies (irradiated patients reconstructed with CAL vs. nonirradiated patients reconstructed with CAL)

First author	Age (years)	Preoperative BMI (kg/m²)	Tumor type	Type of reconstruction	Volume of fat graft (mL)	Follow-up (m)	Volumetric persistence (%)
Irradiated patients reconstructed with CAL
Tissiani LAL ²⁰¹⁶
	55	24.2	LCI	LD + IMPL	45	49	-27.33
	47	25.4	Mucinous	LD + IMPL	92	45	68.17
	48	27.2	DCI	LD + IMPL	137	38	87.20
	41	27.5	DCIS	TRAM	147	37	276.51
	54	24.0	DCI	LD + IMPL	141	34	69.07
	44	23.5	DCI	LD + IMPL	117	33	31.97
	56	23.9	DCI	TRAM	111	33	99.79
	43	30.9	LCI	Seq-explantation	159	20	31.38
mean ± SD	48.5 ± 5.8	25.8 ± 2.6	-	-	118.6 ± 36.8	36.1 ± 8.7	79.6 ± 89.0
Ito S ²⁰¹⁷
	56	21.1	NA	No	120	NA	NA
	56	25.3	NA	No	80	NA	NA
	46	18.4	NA	No	154	NA	NA
	34	19.8	NA	No	84	NA	NA
	53	22.3	NA	No	83	NA	NA
	52	24.4	NA	No	98	NA	NA
	41	19.7	NA	No	50	NA	NA
	45	19.7	NA	No	46	NA	NA
	50	21.6	NA	No	152	NA	NA
	35	20.1	NA	No	70	NA	NA
mean ± SD	46.8 ± 8.1	21.2 ± 2.2	-	-	93.7 ± 37.8	-	-
Jeon HJ ²⁰²¹
	35	20	DCI	LD	120	12	64.1
	46	22.9	DCI	TRAM	200	12	58.5
	36	30.1	DCI	LD	120	12	42.9
mean ± SD	39.0 ± 6.1	24.3 ± 5.2	-	-	146.7 ± 46.2*	12	55.2 ± 11.0*
Nonirradiated patients reconstructed with CAL
Tissiani LAL ²⁰¹⁶
	49	28	DCI	EXP + IMPL	177	38	63.4
	51	28.7	DCI	EXP + IMPL	180	37	95
Jeon HJ ²⁰²¹
	54	26.8	DCI	LD	100	12	68.2
	44	22.7	DCI	LD	50	12	71.1
	49	29.6	DCI	TRAM	60	12	66.4
	64	22.6	LCI	LD	40	12	69.7
	48	26.3	DCIS	LD	120	12	74.6
	42	21.3	DCI	TRAM	100	12	62.8
	38	24.2	DCI	LD	100	12	75.7
mean ± SD	48.4 ± 8.0	24.8 ± 2.7	-	-	81.4 ± 28.5	12	69.8 ± 4.2

CAL Cell-assisted lipotransfer, BMI Body mass index, LCI Lobular carcinoma invasive, DCI Ductal carcinoma invasive, DCIS Ductal carcinoma in situ, LD Latissimus dorsi flap, IMPL Implant, TRAM transverse rectus abdominis myocutaneous flap, EXP Expander, y Year, m Months, NA Not available. * P < 0.05

ISSN: 1477-7819